Phaseline

Targets › HT1A

HT1A: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Psychiatry.

Open in Phaseline: the race on HT1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Reviva PharmaceuticalsBrilaroxazine (RP5063)
Dopamine D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist
DRD2, HT1APhase 3Schizophrenia–

Conditions

Schizophrenia (1)

Modalities

small molecule (1)

Companies

Reviva Pharmaceuticals (1)

Related targets

DRD2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.